Correction to: npj Breast Cancer, published online 08 September 2023 In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy’ and has been corrected to ‘Vimercate Hospital, ASST della Brianza, Vimercate, Italy’. The original article has been corrected.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer / A. Fabi, L. Carbognin, A. Botticelli, I. Paris, P. Fuso, M.C. Savastano, N. La Verde, C. Strina, R. Pedersini, S. Guarino, G. Curigliano, C. Criscitiello, M. Raffaele, A. Beano, A. Franco, M.R. Valerio, F. Verderame, A. Fontana, E.R. Haspinger, A. Caldara, A. Di Leone, G. Tortora, D. Giannarelli, G. Scambia. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 9:1(2023 Oct). [10.1038/s41523-023-00596-1]
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
G. Curigliano;C. Criscitiello;A. Caldara;
2023
Abstract
Correction to: npj Breast Cancer, published online 08 September 2023 In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy’ and has been corrected to ‘Vimercate Hospital, ASST della Brianza, Vimercate, Italy’. The original article has been corrected.
| File | Dimensione | Formato | |
|---|---|---|---|
|
unpaywall-bitstream-1939334705.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
379.54 kB
Formato
Adobe PDF
|
379.54 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
